{"filings":[{"id":96832,"accession_number":"0001213900-26-040458","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adaptin Bio shares approved for OTCQB quotation under ticker APTN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.","Trading expected to begin within the next 6-8 weeks, pending any material updates.","CEO notes lead program APTN-101 is expected to begin a Phase 1 first-in-human trial shortly.","Company develops precision cancer therapeutics targeting brain and difficult-to-reach tissues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127731,"accession_number":"0001213900-25-125451","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Adaptin Bio raises $1M in private placement of 200,000 shares at $5.00 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.0 million from sale of 200,000 shares at $5.00 per share in a private placement.","Placement agent receives 10% cash commission and warrants for 10% of shares sold, exercisable at $5.00 for 5 years.","Company will file resale registration statement; 12% per annum penalty for registration delays.","Holders get piggyback registration rights subject to underwriter cut-back on a pro rata basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127730,"accession_number":"0001213900-25-096532","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Adaptin Bio increases CFO salary to $300k full-time; CDO salary to $150k at 50% commitment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Timothy Maness moved to full-time from 80%; base salary raised from $240k to $300k, retroactive to July 1, 2025.","CDO L. Arthur Hewitt commitment increased from 25% to 50%; salary doubled to $150k annually, effective October 3, 2025.","Hewitt amendment includes anti-dilution option grant if company raises $10M within two years of February 11, 2025 merger.","Both amendments effective as of specified dates; no other material changes to employment terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162862,"accession_number":"0001213900-25-031875","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K/A","filed_at":"2025-04-15T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.","Cash of only $34K as of Dec 31, 2024; accumulated deficit $4.12M.","Auditor expresses substantial doubt about ability to continue as going concern.","Convertible notes payable of $1.25M and derivative liability of $545K recorded.","Deferred equity issuance costs of $194K reflect planned capital raise; management cites need for additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162863,"accession_number":"0001213900-25-030320","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.","Private placement of 1,400,342 shares with Series A (1-yr, $4.40) and Series B (5-yr, $6.60) warrants.","$1.5M promissory notes converted at $3.30/share; total gross proceeds ~$7.7M.","Proceeds to fund Phase 1 trial of APTN-101 for glioblastoma after FDA IND clearance.","Post-closing: Lucius Partners and former Adaptin holders each hold ~3.25M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180808,"accession_number":"0001213900-25-014630","cik":1938571,"company_name":"ADAPTIN BIO, INC.","ticker":"APTN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.01","3.02","1.01","3.03","4.01","5.01","5.02","5.03","5.05","5.06","9.01"],"status":"ready","headline":"Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.","Issued ~3.25M shares to Private Adaptin stockholders; former shell stockholder Lucius Partners retains 3.25M shares.","Concurrent private placement of 1,080,814 Units at $4.40/Unit raised $4,755,581; each Unit: one share, one A warrant, one-half B warrant.","$1.5M bridge notes plus accrued interest converted into 501,140 shares and pre-merger warrants issued.","Company to file resale registration statement within 60 days after offering termination; OTC Markets QB listing planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":0.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}